Applied Case: When “Heart Failure” Is Protein Loss

Lecture collection · Visual teaching summary · October 3, 2026

Andrew Bland, MD, FACP, FAAP

Visual summary

Heavy protein loss can explain “heart-failure” edema; quantify it, establish the glomerular diagnosis, and assess complications before choosing treatment.

Different routes can converge on edema. See the diagram description and full text below.
· Download full-size illustration (PNG) · Download Markdown · Read text version ·

Illustration updated October 18, 2026. Educational schematic. Imaging and microscopy panels are illustrations, not patient studies. Full teaching text and sources follow.

Diagram description

Different routes can converge on edema. Venous congestion — Higher hydrostatic pressure; Glomerular protein loss — Albumin loss and kidney sodium retention; Tissue edema — The same outward sign; Discriminating evidence — Urine protein, sediment, heart and liver assessment. Congestion and nephrotic disease can coexist; do not close the diagnosis after seeing swelling. The infographic uses anatomical illustrations and integrated labels; the complete teaching text and evidence are below.

Text version

Reopen the edema diagnosis

Case 16 illustrates persistent swelling attributed to heart failure. Ask whether cardiac findings explain the degree of edema. Check foamy urine, serum albumin, urine dipstick, and protein quantification rather than intensifying cardiac therapy without a renal assessment.

Confirm the nephrotic syndrome

Heavy proteinuria—classically >3.5 g/day in adults—plus hypoalbuminemia and edema supports nephrotic syndrome. A spot protein:creatinine ratio helps quantify it, but collection and muscle mass affect interpretation. Nephrotic-range proteinuria alone is not the complete syndrome.

Use sediment and secondary clues

Hematuria/casts or rapidly declining function suggest a mixed inflammatory process. Review diabetes, autoimmune symptoms, infection, malignancy, and medicines. Select complements, autoantibodies, infection tests, or monoclonal-protein studies from the clinical pattern rather than ordering an indiscriminate panel.

Identify the disease before immunotherapy

PLA2R antibody testing can support membranous nephropathy in a compatible setting; biopsy is needed in many uncertain or atypical cases. Integrate pathology with serology and kidney trajectory. Edema severity alone cannot select rituximab, glucocorticoids, or another immunosuppressant.

Treat symptoms and reduce protein loss

Plan sodium reduction and diuresis while monitoring perfusion, weight, kidney function, and electrolytes. Use indicated antiproteinuric therapy when tolerated. Albumin infusion is not routine for every low albumin result; persistent refractory edema needs a focused specialist plan.

Screen for complications

New unilateral leg swelling, pleuritic pain, or unexplained dyspnea raises thromboembolism concern. Anticoagulant prophylaxis requires a disease-specific thrombosis-versus-bleeding assessment, not automatic treatment of every nephrotic patient. Reassess infection risk, nutrition, and the coexistence of genuine heart disease.

Supporting evidence

Continue learning